[Efficacy of prostaglandin E1 in treatment of cor pulmonale patients with heart failure].
To investigate the effects of prostaglandin E1 (PGE1) by intravenous drip in cor pulmonale patients with heart failure. Thirty caseas of cor pulmonale with heart failure were treated with PGE1 at a dose of 200 micrograms.d-1 for 5 days and in 30 patients with cor pulmonale heart failure (no PGE1) and in 20 healthy subjects as controls. The level of serum endogenous digoxin-like factor (EDF), serum lipoid superoxide (LPO), serum superoxide dismutase (SOD) and blood PaO2, PaCO2 were determined. Their symptoms and signs were observed before and after treatment. The level of serum EDF, LPO were significantly increased (P < 0.001) and serum SOD was significantly decreased (P < 0.001) in PGE1 group and controls group (no PGE1) as compared with healthy subjects. In PGE1 group the level of serum EDF, LPO were markedly decreased (P < 0.001), and serum SOD was markedly elevated (P < 0.001), and their symptoms, signs and blood gas parameters had noteworthyly improved (P < 0.01-0.001). But in the control group (no PGE1) the level of serum EDF, LPO, SOD, blood gas parameters and their symptoms and signs, showed no significant difference (P > 0.05). PGE1 is effective in therapy of cor pulmonale with heart failure. Treatment with PGE1 shows more significant benefits in cor pulmonale patients with heart failure.